Evidence map›Paper›PMID 39258287›Full record

ReviewJID innovations : skin science from molecules to population health2024

Metastatic Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patient: A Systematic Review.

Megan Wackel, Sierra Thomas, Cynthia M Schmidt, Cheng Zheng, Ashley Wysong, Melodi J Whitley

Abstract readReview
In one paragraph

Review in JID innovations : skin science from molecules to population health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Megan WackelDepartment of Dermatology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Sierra ThomasDepartment of Dermatology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Cynthia M SchmidtLeon S. McGoogan Heath Sciences Library, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Cheng ZhengDepartment of Biostatistics, College of Public health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Ashley WysongDepartment of Dermatology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Melodi J WhitleyDepartment of Dermatology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Funding

Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

Patients who are immunosuppressed, such as solid organ transplant recipients (SOTRs), are at a higher risk of developing cutaneous squamous cell carcinoma (cSCC). This population is at a higher risk of metastasis and worse disease-specific survival. The objective of this review is to better characterize the immunosuppressed population with metastatic cSCC. A literature search was conducted to identify reports of lymphatic metastases in immunosuppressed patients with cSCC. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed during creation of a cohort with desired inclusion and exclusion criteria. One hundred and thirty-five articles met the inclusion/exclusion criteria, yielding 1020 total cases. We discovered that the most common forms of immunosuppression within the cohort were solid organ transplantation and hematologic malignancy. White males and cSCC tumors involving the head and neck comprised most cases. Using Brigham and Women's Hospital and Eighth edition of American Joint Committee on Cancer tumor staging criteria, we observed a trend toward higher stage tumors in SOTR than in patients with hematologic malignancy. This review confirms that known clinical risk factors for metastatic cSCC appear to be similar among the immunosuppressed population and the cSCC population at large. Interestingly, our data suggest that current staging systems may not accurately reflect metastatic risk among patients with hematologic malignancy.

Indexed as

ImmunodeficienciesMetastasisSquamous cell carcinoma

Identifiers

PMID39258287
PMCPMC11385752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.